We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
WHX Labs Dubai 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Miniature Swine May Be Future Organ Donors

By Biotechdaily staff writers
Posted on 20 May 2002
In a major achievement that brings scientists closer to making animal-to-human transplantation a reality, miniature swine engineered to avoid rejection in humans have been successfully cloned by researchers from the University of Missouri (Columbia, USA) and Immerge BioTherapeutics Inc. (Charlestown, MA, USA). The research is reported online by the journal Science at the Science Express website (www.sciencexpress.org). Immerge BioTherapeutics is a joint venture of BioTransplant Inc. and Novartis Pharma AG.

Overcoming the human body's massive immune response after perceiving a foreign organ is the greatest challenge in xenotransplantation. The hyperacute rejection occurs when human antibodies attach to sugar molecules on the surface of the transplanted organ's cells. Once they attach, the antibodies kill the cells. In this new line of miniature swine, however, the gene that produces this sugar molecule, called –1,3-galactosyltransferase (GGTA1), was "knocked out” of their DNA. Without the sugar, the antibodies don't attach and the rejection process cannot begin.

The researchers report that this is the first targeted modification of the pig genome and only the second in any large animal. Also, these swine are the first nuclear transfer-derived miniature swine. The researchers have been developing a line of miniature swine that offers advantages for transplantation. One is the organ size, which is appropriate for human recipients. Another advantage is that cells from this line of pigs, in contrast to other cells, have shown they do not have the capacity to spread porcine endogenous retrovirus to human cells in culture.

"We believe this line of miniature swine offers the greatest potential for clinical use in humans, and we're working closely with the University of Missouri-Columbia and our commercial partner, Infigen Inc., to develop these swine with this goal in mind,” said Robert Hawley, Ph.D., associate director of animal genetic engineering at Immerge BioTherapeutics.




Related Links:
Univ. of Missouri
Science Express

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Gel Cards
DG Gel Cards

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
20 May 2002  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
20 May 2002  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
20 May 2002  |   BioResearch